We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Arcus Biosciences Inc (RCUS) COM USD0.0001

Sell:$44.24 Buy:$44.26 Change: $0.79 (1.76%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.79 (1.76%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.79 (1.76%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapies. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. It is focused on creating, developing and commercializing differentiated combination cancer therapies. The Company has five products in clinical development: Domvanalimab, Etrumadenant, Quemliclustat, AB308 and Zimberelimab. Domvanalimab is designed for immune activation and tumour clearance in combination with other immunotherapy and anti-cancer agents. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumour-infiltrating lymphocytes and myeloid cells. Quemliclustat is designed to provide differential benefits relative to monoclonal antibodies. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody.

Contact details

3928 Point Eden Way
United States
+1 (510) 6946200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.03 billion
Shares in issue:
70.25 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Terry Rosen
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Juan Jaen
    President, Co-Founder, Director
  • Robert Goeltz
    Chief Financial Officer, Principal Financial and Accounting Officer
  • Jennifer Jarrett
    Chief Operating Officer, Director
  • Carolyn Tang
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.